Business
IB Opens Expanded Access Program
IB Opens Expanded Access Program.
About this update from Imaging Biometrics Limited
[{"type":"text","content":"\n\nJune 25, 2024\nIQ-AI Ltd\n(\"IQ-AI\" or the \"Company\")\n \nImaging Biometrics Opens Expanded Access Program\nNew cancer treatment with the potential to slow brain tumor growth is now available to patients in the US with relapsed/refractory histologic or molecular glioblastoma\nImaging Biometrics, LLC (\"IB\"), the Wisconsin USA based subsidiary of IQ-AI (LSE: IQAI), announces that the US Food and Drug Administration (\"FDA\") has approved an Expanded Access Program (\"EAP\") for oral gallium maltolate (\"GaM\").\nThis EAP will run in parallel with the current phase 1 clinical trial being conducted at the Medical College of Wisconsin (\"MCW\"). As the phase 1 trial concludes this fall and while the data is being compiled, eligible patients in the US will have the option of participating in the EAP. Several patients have registered to participate in the EAP, and a total of 40 patients can enrol in this initial phase.\n\"Providing eligible patients access to GaM as a potential treatment ahead of regulatory approval underscores our commitment to helping address a clear unmet patient need,\" said Trevor Brown, CEO of IQAI.\n \n--ENDS-\n \nThe Directors of the Company accept responsibility for the contents of this announcement.\n \nFor further information, please contact:\n \n\n\n\n\nIQ-AI Ltd\nTrevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda\nTel: 020 7469 0930\n\n\n\n\nPeterhouse Capital Limited (Financial Adviser and Broker)\nLucy Williams/Heena Karani\nTel: 020 7220 9797\n\n\n\n\nAbout Imaging Biometrics® LLC: IB is a wholly owned subsidiary of IQ-AI Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com. Follow IB on Twitter, @IQAI_IB. \n \n \n \n\n","length":3832,"tagName":"div"}]